Search

UBS AG said that it will make public its preliminary earnings for the 2000 third-quarter earlier than expected. The move is intended to guarantee a maximum amount of transparency during UBS' merger with PaineWebber Group Inc.

Ciba Specialty Chemicals Holding AG posted an increase of 65% in its net income for the nine-month period ending September 30, 2000. The company posted 329 million Swiss francs (218 million euros) in net income for the period.

Commerzbank AG posted a higher net income for the 2003 second quarter. The firm posted 70 million euros in net income, compared to 2 million euros in the same 2002 period.

Speedel Group, a Swiss drug-development firm, has secured financing from Novartis AG and is planning to introduce Aliskiren, a high-blood pressure medication. This funding will allow the company to move Aliskiren, a renin inhibitor, through the final stages of drug development.

Roche Holding AG posted a 4.03 billion francs net loss for the 2002 year. The company assumed a 9.4 billion Swiss franc charge for portfolio losses and litigation.

Novartis AG is expected to post a rise of 5.6% in its 2002 fourth quarter net income. The company benefitted from the strength of the Swiss franc.

Regulators in Holland have approved Schering AG's Angeliq hormone replacement drug. The approval came two months after the menopause drug was rejected by US Food and Drug Administration.

Oxford Glycosciences PLC has received European Commission approval for its Zavesca drug. The drug is designed to treat patients suffering from the Gaucher disease.

Antisoma PLC has granted the rights to its cancer drugs to Roche Holding AG. Roche's cancer drug portfolio will be strengthened by this licensing deal with Antisoma.

Aventis SA posted an increase of 21% in its profits for the 2002 third-quarter. The company posted 560 million euros in net profits for the period.

GlaxoSmithKline PLC claims that producers of generic drugs are making a antibiotic drug based on trade secrets that have been stolen from the company. Glaxo says that generic drug firms are producing a version of its Augmentin antibiotic with the help of its trade secrets.

Syngenta AG posted an increase of 12% in its net profits for the 2002 first-half. The company, helped by cost savings and reduced taxes, posted $448 million (463.9 million euros) in net profits for the period.

Actelion AG has reached a marketing agreement with Oxford GlycoSciences. Under the deal, Actelion will market Oxford's Zavesca drug for the Gaucher disease. Actelion will also monitor the drug's usage.

Serono S.A. posted a drop of 8.7% in its net income for the 2002 second-quarter. The company, which posted $95.2 million in quarterly net income, also reduced its forecast for the full year period.

Croatian-based Pliva has reached a deal to acquire Sidmak Laboratories Inc. and its subsidiary, Odyssey Pharmaceuticals Inc. from Sobel N.V. The deal is valued at $152.9 million (162.1 million euros) in cash.

Clariant AG announced that it has lowered its financial debt by up to 17%. The company has reduced its debt to 4.28 billion Swiss francs (2.9 billion euros). Analysts had predicted Clariant to reduce its debt to 4.8 billion Swiss francs.

Serono S.A. posted a rise of 5.2% in its net profits for the 2001 year. The company, helped by its Rebif drug sales, posted $316.7 million (361.3 million euros) in net profits for the full-year period.

As part of a strategic partnership between the two companies, Schering AG has reached a deal to acquire a minority share of MorphoSys AG. Schering will acquire 10% of MorphoSys. Both firms will also conduct joint development of diagnostic tests and antibody drugs.

BASF AG posted a drop of 22% in its sales for the 2001 third-quarter. The company posted 7.2 billion euros in sales for the period.

Bayer AG is expected to post lower than expected results for the 2001 third-quarter. The company is forecasted to report a 5.7% drop in its quarterly sales to 7.24 billion euros.

Serono S.A. posted lower-than-expected sales for the 2001 third-quarter. The company posted a 4.9% rise in quarterly sales to $295.4 million.

Clariant AG posted a drop of 4% in its 2001 nine-month sales to 7.59 billion Swiss francs. The company also posted a 9.5% drop in sales for the third-quarter period.

Actelion AG is close to launching its Tracleer pulmonary hypertension drug on the market. Tracleer was given regulatory approval by the U.S. Food and Drug Administration.

Celanese AG reduced its earnings forecast for the full 2001 year for the second time in a month. The company blamed the reduced forecast on the slowdown in the chemical industry.

BASF AG's second-quarter results were not as high as expected. Profit plummeted 17% to Euro751 million from a year ago. The Germany company posted a less optimistic mid-term outlook.

Merck KGaA is forecasted to post strong results for the 2001 first-half. The company is expected to post a 15% rise in operating profits for the period to 421 million euros.

Bank Sarasin saw its share value rise by 12% on the possibility of a acquisition offer by UBS AG. UBS is considering either an acquisition or a partnership with Sarasin.

Stockholders of the Swiss travel agency Kuoni Reisen Holding have settled dispute with the chairman Daniel Affolter, who resigned his position.

Degussa AG is planning to sell its Degussa Dental unit to Dentsply International Inc. The deal is valued at 576 million euros in cash.

Aventis SA's CropScience unit posted an improvement of 21% in its earnings for the 2001 first-quarter. The company, which posted 265 million euros in quarterly earnings, will see its chances for divestment greatly improved by the results.

Serono SA posted an increase of almost 14% in its 2001 first-quarter sales. The company posted $294.4 million (330.1 million euros) in sales for the period.

BASF AG posted an increase of 4.2% in its operating profits for the 2001 first-quarter. The company posted 962 million euros in operating profits for the period. However, some of BASF's divisions are struggling, paving the way for 'less bullish' 2001 second-half.

Schering AG expects to see 15% to 20% growth in net income for the 2001 year. The company posted an increase of 2.1% in its operating profits for the 2001 first-quarter.